What AccuGenomics does

AccuGenomics, Inc. is a privately held molecular diagnostics company founded in 2010 and headquartered in Wilmington, North Carolina. The company develops and commercializes SNAQ-SEQ, a proprietary multiplexed spike-in quality control technology for next-generation sequencing (NGS) assays. SNAQ-SEQ internal standards are added directly into each sample and co-vary through the entire workflow — chemistry, flow cell detection, and bioinformatics — providing per-sample measurement of technical and systemic errors, true Limit of Blank (LOB) and Limit of Detection (LOD) values, and elimination of false positives and false negatives at low variant allele frequencies. The underlying technology is exclusively licensed from the University of Toledo and protected by U.S. Patent No. 9,944,973.

The company sells a catalog of Accukit products targeting oncology (ctDNA MRD, CRC/NSCLC, Myeloid DNA, Onco1 LB, Mammo DNA), infectious disease (SARS-CoV-2), and biopharmaceutical manufacturing QC (Adventitious Agents AA20 for CHO cell bioproduction). AccuGenomics also offers a Custom Design Service producing client-specific SNAQ-SEQ standard mixes in as few as six weeks, and pursues companion diagnostics co-development partnerships with biopharma and diagnostic companies. Revenue derives from one-time catalog product sales, professional services for custom design work, and licensing royalties on the platform IP. The company operates with a 1-10 employee headcount out of a 5,000+ sq ft development and manufacturing facility, distributing through direct enterprise sales, regional distributors (SOMAGEN Diagnostics in Canada, MITEK Lab in Taiwan), and strategic channel partnerships including a 2024 alliance with LGC Clinical Diagnostics and a 2025 collaboration with 1Cell.Ai for liquid biopsy deployment in India and the U.S. The company is regulated-grade validated via FDA-led SEQC2 consortium participation and FNIH Biomarkers Consortium membership for MRD in AML.

Name

AccuGenomics

Legal name

AccuGenomics, Inc.

Website

https://accugenomics.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

AccuGenomics is a Wilmington, NC-based molecular diagnostics company that develops and sells SNAQ-SEQ spike-in internal standards and Accukit product kits for NGS quality control, serving biopharmaceutical manufacturers, clinical diagnostics companies, and academic oncology research centers.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)

Keywords

• NGS quality control
• Spike-in standards
• Molecular diagnostics reagents
• Clinical sequencing assays
• Companion diagnostics development

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Accukit Products: Sale of pre-configured spike-in QC standard kits including Accukit ctDNA MRD IS, Accukit Mammo DNA IS, Accukit CRC/NSCLC IS, Accukit Myeloid DNA, AccuKit Onco1 LB, AccuKit SARS-CoV-2, and Accukit Adventitious Agents (AA20). Products are sold for research use and targeted at biopharmaceutical manufacturers and clinical diagnostics companies.
2. Custom Design Services: Custom spike-in DNA or RNA standard mixes designed and developed for specific customer applications. Custom mixes can range from 6 to 66+ unique control regions.
3. Licensing Royalties: Technology licensed from University of Toledo for SNAQ-SEQ platform. Company holds exclusive license to patented technologies.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

AccuGenomics develops and sells SNAQ-SEQ multiplexed spike-in quality control standards that co-vary with patient samples through the entire next-generation sequencing workflow to provide direct measurement of technical and systemic errors per sample. Its Accukit product line of catalog internal standard kits addresses cancer diagnostics (ctDNA MRD, CRC/NSCLC, Myeloid DNA, Onco1 LB, Mammo DNA), infectious disease (SARS-CoV-2), and biomanufacturing QC (Adventitious Agents AA20), complemented by a Custom Design Service for bespoke spike-in mixes.

Product overview

AccuGenomics is a commercial-stage molecular diagnostic company offering a portfolio of multiplexed spike-in quality control (QC) standards branded as SNAQ™-SEQ. The core product line includes: SNAQ™-SEQ Internal Standards (the foundational technology platform), specialized Accukit products for specific applications (ctDNA MRD IS, CRC/NSCLC IS, Myeloid DNA IS, Onco1 LB, SARS-CoV-2, Adventitious Agents AA20), and Custom Design Services. These products serve as run controls that co-vary with samples through NGS workflows to measure technical errors, establish limits of blank, and ensure assay sensitivity. The portfolio covers applications including cancer diagnostics (liquid biopsy, MRD, CNV detection), infectious disease testing (SARS-CoV-2, adventitious agents), and biopharmaceutical manufacturing QC.

Differentiator

Problem solved

Functional benefit

Brands

• SNAQ-SEQ: Spike-in quality control technology for next-generation sequencing applications that enables highly sensitive NGS and provides internal standards to improve assay accuracy and performance.
• Accukit
• STARSEQ

Products and services

• SNAQ-SEQ Internal Standards
• Accukit ctDNA MRD IS
• Accukit Mammo DNA IS Internal standards designed for mammography-related DNA applications in cancer diagnostics, providing SNAQ-SEQ spike-in controls for breast cancer NGS assays.
• Accukit CRC/NSCLC IS Internal standards collection for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) testing. Contains 13 clinically actionable targets including KRAS (G12D/C), EGFR (L858R, T790M), BRAF (V600E), AKT1 (E17K), ERBB2, KIT, NRAS, GNAS, BRCA2, and ESR1 variants. Compatible with amplicon and hybrid capture workflows including Illumina TST-170 and TSO500.
• Accukit Myeloid DNA IS Internal standards for acute myeloid leukemia (AML) testing and measurable residual disease (MRD) detection. Provides variant-specific sensitivity controls for therapeutically relevant AML targets in each sample. Compatible with hybrid capture and amplicon-based library prep chemistries, available pre-fragmented for blood/plasma (cfDNA) or unfragmented for FFPE/tissues.
• AccuKit Onco1 LB Blend of 13 synthetic DNA internal standards for clinically actionable oncogenic regions of the genome. Designed for ctDNA-based NGS hotspot assays, measuring variant allele frequencies. Provides sequence accuracy (limit of blank) and sensitivity control (limit of detection) for MRD applications. Fragmented to ~165bp average size for cell-free DNA assays.
• AccuKit SARS-CoV-2 First SARS-CoV-2 standard designed specifically for NGS applications. Contains 17 synthetic RNA overlapping constructs spanning the entire SARS-CoV-2 genome plus a complexity control (65k unique molecules). Co-locates with sample through RT step to control for systemic and technical errors, measure background error, and provide LOD control for qualitative detection assays.
• Accukit Adventitious Agents (AA20) NGS-library prep workflow for 20 common adventitious agents found in Chinese hamster ovary (CHO) cell bioproduction processes. Achieves sensitivity of 10 copies of target per ml of lysate. Includes targets such as Bovine adenovirus, Bovine coronavirus, Bovine parvovirus, Minute virus of Mice, Porcine Circovirus, and Seneca Valley Virus. Uses matched DNA and RNA SNAQ-SEQ spike-in standards.
• Custom Design Service Custom SNAQ-SEQ internal standards development service. Provides custom spike-in DNA or RNA standard mixes in as little as 6 weeks. Supports custom internal standards mixes to enhance CNV detection, monitor viral pathogens, and improve variant allele frequency detection for ctDNA and FFPE tumor specimens. Custom mixes can range from 6 to 66+ unique control regions. Includes custom SNAQ-SEQ analysis tools development.

Quantifiable outcome

• 20-fold reduction in sequencing requirements while maintaining accuracy
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• 1Cell.AicoreStrategic or Co-development Partner · 13 October 2025Strategic collaboration to deliver ultra-sensitive liquid biopsy testing in India with plans to expand to the US. AccuGenomics will integrate its internal standards into 1Cell.Ai's liquid biopsy platform. The partnership aims to process tens of thousands of patient samples and improve cancer diagnostics accuracy across Asia and the US. Expected to enhance clinical reliability and support precision oncology.
• 1Cell.AicoreTechnology or Integration · 13 October 2025Integration of AccuGenomics' SNAQ-SEQ internal standards into 1Cell.Ai's liquid biopsy platform for improved testing accuracy.
• LGC Clinical DiagnosticscoreStrategic or Co-development Partner · 8 October 2024Partnership to jointly develop quality control materials for next-generation sequencing tests. Collaboration will leverage LGC's expertise in quality control and AccuGenomics' NGS monitoring technologies. Goal is to develop accurate and reliable molecular diagnostics and quality control materials for cancer NGS testing as well as custom reference materials for NGS assay validation.
• University of ToledocoreTechnology or IntegrationAccuGenomics holds exclusive license to suite of patented technologies from the University of Toledo that enable advanced genomic testing applications. SNAQ-SEQ technology originated from collaboration with University of Toledo and the Innovative Molecular Analysis Technologies Program of the NIH.
• FNIH Biomarkers ConsortiumcoreStrategic or Co-development PartnerAccuGenomics joined the FNIH Biomarkers Consortium focused on Measurable Residual Disease in Acute Myeloid Leukemia (MRD in AML). Participation advances accuracy of targeted NGS testing of liquid biopsy samples. The FNIH Biomarkers Consortium is the preeminent public-private partnership focused on identifying, developing, and qualifying biomarkers that accelerate therapeutics and improve clinical care.
• SOMAGEN DIAGNOSTICSminorChannel Partner/ Reseller/ DistributorAuthorized distributor for AccuGenomics products in Canada.
• MITEK LAB CO LTDminorChannel Partner/ Reseller/ DistributorAuthorized distributor for AccuGenomics products in Taiwan.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• LGC Clinical Diagnostics: LGC is a global life sciences measurement and diagnostics consumables leader whose portfolio includes NGS reference standards and QC materials — directly overlapping AccuGenomics' SNAQ-SEQ catalog. Note: LGC is also AccuGenomics' partner, making the relationship both collaborative and competitive.
• Bio-Rad Laboratories: Bio-Rad's Life Science segment supplies a broad catalog of molecular and NGS QC reagents, controls, and reference standards used in clinical genomics workflows — directly comparable to AccuGenomics' Accukit catalog across oncology, infectious disease, and biopharma QC.
• Revvity (formerly Horizon Discovery): Revvity's genomics/reagents business (built on the legacy Horizon Discovery reference standards franchise) is one of the closest direct competitors in synthetic NGS reference materials and controls for oncology and liquid biopsy assays.
• ATCC: ATCC produces authenticated biological reference materials, microbial and viral standards, and genomic reference DNA/RNA used as benchmarks in NGS assay validation — overlapping directly with AccuGenomics' reference-standard role across infectious disease and oncology.
• Integrated DNA Technologies (IDT / Danaher): IDT supplies a broad NGS reagent portfolio including capture/library prep and quality controls used by diagnostic and biopharma labs, putting it adjacent to AccuGenomics' SNAQ-SEQ standards as a complement or substitute in commercial NGS workflows.
• Promega Corporation: Promega manufactures nucleic acid purification, amplification, and quantification reagents including Maxwell and GoTaq lines used in clinical molecular labs — providing established alternatives to AccuGenomics on workflow control and detection chemistries.
• Eurofins Genomics: Eurofins operates one of the largest global genomics service and reagent footprints including NGS reference materials and synthetic spike-in controls used by clinical and biopharma customers — comparable distribution scale and consumables catalog breadth.

Direct peers

• Twist Bioscience: Twist's synthetic biology platform supplies custom DNA controls, NGS target enrichment probes, and reference standards used in clinical and biopharma NGS workflows — closely comparable to AccuGenomics' custom SNAQ-SEQ design service.
• SeraCare (LGC subsidiary): SeraCare (now part of LGC Clinical Diagnostics) is a longstanding supplier of ctDNA, oncology, and infectious-disease reference standards for NGS assay validation — overlapping with multiple Accukit product lines including ctDNA MRD IS, Myeloid DNA IS, and SARS-CoV-2 standards.
• 1Cell.Ai: 1Cell.Ai is AccuGenomics' explicit commercial partner and an emerging player in liquid biopsy testing; the two firms share the same end-customers (clinical NGS users) and overlap directly in ctDNA/liquid biopsy assay workflows, with AccuGenomics' standards integrated into 1Cell.Ai's platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/accugenomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AccuGenomics